Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.

Summary

To evaluate the safety of \[64Cu\] Macrin and its whole-body distribution, metabolism, pharmacokinetics, and radiation burden in healthy volunteers. To detect \[64Cu\]-Macrin accumulation in sites of disease in subjects with cancer, sarcoidosis or myocardial infarct.

Timeline

Start

2021-09-06

Primary completion

2023-04-05

Completion

2023-04-05

Publications

• O'Shea A, Lewis AJM, Caravan P, Izquierdo-Garcia D, Le Fur M, Catalano OA, Montesi SB, Quintana JM, Carlson JCT, Dubach JM, Castro CM, Bobic M, Huesa-Berral C, Ng TSC, Bertolet A, Nahrendorf M, Weissleder R. First-in-Human Study of the Carbohydrate Nanoparticle 64Cu-Macrin. J Nucl Med. 2026 Mar 2;67(3):449-455. doi: 10.2967/jnumed.125.270770.

Drugs

Indications